TY - JOUR
T1 - Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia
T2 - Genotype signatures for response and survival among 301 consecutive patients
AU - Gangat, Naseema
AU - Karrar, Omer
AU - Iftikhar, Moazah
AU - McCullough, Kristen
AU - Johnson, Isla M.
AU - Abdelmagid, Maymona
AU - Abdallah, Mostafa
AU - Al-Kali, Aref
AU - Alkhateeb, Hassan B.
AU - Begna, Kebede H.
AU - Mangaonkar, Abhishek
AU - Saliba, Antoine N.
AU - Hefazi Torghabeh, Mehrdad
AU - Litzow, Mark R.
AU - Hogan, William
AU - Shah, Mithun
AU - Patnaik, Mrinal M.
AU - Pardanani, Animesh
AU - Badar, Talha
AU - Murthy, Hemant
AU - Foran, James
AU - Palmer, Jeanne
AU - Sproat, Lisa
AU - Khera, Nandita
AU - Arana Yi, Cecilia
AU - Tefferi, Ayalew
N1 - Publisher Copyright:
© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.
PY - 2024/2
Y1 - 2024/2
N2 - Venetoclax + hypomethylating agent (Ven-HMA) is currently the standard frontline therapy for older/unfit patients with newly diagnosed acute myeloid leukemia (ND-AML). Our objective in the current retrospective study of 301 adult patients (median age 73 years; 62% de novo) with ND-AML was to identify molecular predictors of treatment response to Ven-HMA and survival; European LeukemiaNet (ELN) genetic risk assignment was favorable 15%, intermediate 16%, and adverse 69%. Complete remission, with (CR) or without (CRi), count recovery, was documented in 182 (60%) patients. In multivariable analysis, inclusive of mutations only, “favorable” predictors of CR/CRi were NPM1 (86% vs. 56%), IDH2 (80% vs. 58%), and DDX41 (100% vs. 58%) and “unfavorable” TP53 (40% vs. 67%), FLT3-ITD (36% vs. 63%), and RUNX1 (44% vs. 64%) mutations; significance was sustained for each mutation after adjustment for age, karyotype, and therapy-related qualification. CR/CRi rates ranged from 36%, in the presence of unfavorable and absence of favorable mutation, to 91%, in the presence of favorable and absence of unfavorable mutation. At median follow-up of 8.5 months, 174 deaths and 41 allogeneic stem cell transplants (ASCT) were recorded. In multivariable analysis, risk factors for inferior survival included failure to achieve CR/CRi (HR 3.4, 95% CI 2.5–4.8), adverse karyotype (1.6, 1.1–2.6), TP53 mutation (1.6, 1.0–2.4), and absence of IDH2 mutation (2.2, 1.0–4.7); these risk factors were subsequently applied to construct an HR-weighted risk model that performed better than the ELN genetic risk model (AIC 1661 vs. 1750): low (n = 130; median survival 28.9 months), intermediate (n = 105; median 9.6 months), and high (n = 66; median 3.1 months; p <.001); survival in each risk category was significantly upgraded by ASCT. The current study identifies genotype signatures for predicting response and proposes a 3-tiered, CR/CRi-based, and genetics-enhanced survival model for AML patients receiving upfront therapy with Ven-HMA.
AB - Venetoclax + hypomethylating agent (Ven-HMA) is currently the standard frontline therapy for older/unfit patients with newly diagnosed acute myeloid leukemia (ND-AML). Our objective in the current retrospective study of 301 adult patients (median age 73 years; 62% de novo) with ND-AML was to identify molecular predictors of treatment response to Ven-HMA and survival; European LeukemiaNet (ELN) genetic risk assignment was favorable 15%, intermediate 16%, and adverse 69%. Complete remission, with (CR) or without (CRi), count recovery, was documented in 182 (60%) patients. In multivariable analysis, inclusive of mutations only, “favorable” predictors of CR/CRi were NPM1 (86% vs. 56%), IDH2 (80% vs. 58%), and DDX41 (100% vs. 58%) and “unfavorable” TP53 (40% vs. 67%), FLT3-ITD (36% vs. 63%), and RUNX1 (44% vs. 64%) mutations; significance was sustained for each mutation after adjustment for age, karyotype, and therapy-related qualification. CR/CRi rates ranged from 36%, in the presence of unfavorable and absence of favorable mutation, to 91%, in the presence of favorable and absence of unfavorable mutation. At median follow-up of 8.5 months, 174 deaths and 41 allogeneic stem cell transplants (ASCT) were recorded. In multivariable analysis, risk factors for inferior survival included failure to achieve CR/CRi (HR 3.4, 95% CI 2.5–4.8), adverse karyotype (1.6, 1.1–2.6), TP53 mutation (1.6, 1.0–2.4), and absence of IDH2 mutation (2.2, 1.0–4.7); these risk factors were subsequently applied to construct an HR-weighted risk model that performed better than the ELN genetic risk model (AIC 1661 vs. 1750): low (n = 130; median survival 28.9 months), intermediate (n = 105; median 9.6 months), and high (n = 66; median 3.1 months; p <.001); survival in each risk category was significantly upgraded by ASCT. The current study identifies genotype signatures for predicting response and proposes a 3-tiered, CR/CRi-based, and genetics-enhanced survival model for AML patients receiving upfront therapy with Ven-HMA.
UR - http://www.scopus.com/inward/record.url?scp=85179308472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85179308472&partnerID=8YFLogxK
U2 - 10.1002/ajh.27138
DO - 10.1002/ajh.27138
M3 - Article
C2 - 38071734
AN - SCOPUS:85179308472
SN - 0361-8609
VL - 99
SP - 193
EP - 202
JO - American journal of hematology
JF - American journal of hematology
IS - 2
ER -